2021
-
Collaboration with Richard Childs, M.D., yields potentially first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma
2020
-
2020.12.02 | Adagene Announces Expansion of Leadership Team to Support Strategic Growth
Adagene today announced the expansion of its leadership team. The Company also recently secured laboratory and office space in San Diego to establish a center of excellence for precision medicine and to support its growth in the United States.
-
2020.06.10 | Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories
Tanabe Research Labs and Adagene to develop a first-in-class therapeutic with a next-generation masked antibody drug conjugate (ADC), incorporating Adagene’s SAFEbody™ technology platform
-
Adagene, Inc. a platform-driven, clinical-stage company, today announced that positive results of its novel anti-CD137 agonist, ADG106, from the Phase I trial in China will be presented in a poster at the 2020 American Society of Clinical Oncology (ASCO) Annual meeting.
-
2020.01.09 | Adagene to Present at the 38th Annual J.P. Morgan Healthcare Conference
Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced that Peter Luo, Ph.D., Co-founder and Chief Executive Officer, will present an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference.
-
2020.01.08 | Adagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic
Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced the completion of a $69 million Series D financing, including $50 million from lead investor General Atlantic.
2019
-
2019.10.26 | Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
Adagene Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, announced that it is presenting its lead program at international conferences.
-
2019.04.24 | Adagene and ADC Therapeutics Announce SAFEbody™ License Agreement
Adagene Inc., an antibody engineering and discovery company , and ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that they have entered into a discovery collaboration and license agreement.
-
2019.03.04 | Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation
Adagene, Inc., an innovative antibody discovery and engineering company, today announced a multi-target platform evaluation with Celgene Corporation. Under the terms of the agreement, Adagene will use its Dynamic Precision Library, to discover antibodies against targets chosen by Celgene.
-
Adagene, Inc., an innovative antibody discovery and engineering company, today announced a collaboration with Dr. Richard Childs, Chief of the Laboratory of Transplantation Immunotherapy at the National, Heart, Lung, and Blood Institute, part of the National Institutes of Health, to discover antibodies targeting a novel antigen expressed on the surface of tumor cells.
2018
-
2018.10.31 | Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106
Adagene, Inc., an innovative antibody engineering and discovery company, today announced the dosing of its first patient in its Phase I trial in American for its lead product ADG-106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137.
-
2018.07.09 | US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lymphoma Ph1 Trial
Adagene, Inc., an innovative antibody engineering and discovery company, has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.
-
2018.03.26 | Adagene Raises $50 Million in Series C Funding
Adagene Inc., a leading antibody discovery and development company, today announced a $50 million Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.
-
2018.03.09 | Adagene and WuXi Biologics Announce Strategic Development and Manufacturing Partnership
Adagene Inc., an emerging biotech company discovering and developing innovative antibody therapeutics for the global market, and WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced a strategic collaboration agreement.